OSE.PA Stock - OSE Immunotherapeutics S.A.
Unlock GoAI Insights for OSE.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $69.88M | $2.23M | $18.30M | $26.31M | $10.42M |
| Gross Profit | $69.88M | $2.23M | $18.30M | $26.31M | $10.42M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $43.73M | $-22,986,000 | $-18,476,000 | $-16,625,000 | $-18,989,000 |
| Net Income | $37.45M | $-23,003,000 | $-17,760,000 | $-16,850,000 | $-16,555,000 |
| Net Margin | 53.6% | -1032.9% | -97.0% | -64.1% | -158.9% |
| EPS | $1.72 | $-1.18 | $-0.96 | $-0.93 | $-1.06 |
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.
Visit WebsiteEarnings History & Surprises
OSE.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | — | — | — | — |
Q3 2025 | Sep 25, 2025 | — | $-0.68 | — | — |
Q1 2025 | Mar 26, 2025 | — | $-0.91 | — | — |
Q3 2024 | Sep 27, 2024 | — | $2.63 | — | — |
Q1 2024 | Mar 27, 2024 | — | $-0.54 | — | — |
Q3 2023 | Sep 27, 2023 | — | $-0.64 | — | — |
Q2 2023 | Apr 27, 2023 | $-0.37 | $-0.86 | -131.1% | ✗ MISS |
Q3 2022 | Sep 22, 2022 | $-0.33 | $-0.11 | +67.6% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | $-0.56 | $-0.29 | +48.2% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $0.15 | $-0.64 | -525.3% | ✗ MISS |
Q2 2021 | May 26, 2021 | $-0.53 | $-0.84 | -58.3% | ✗ MISS |
Q3 2020 | Sep 17, 2020 | $-0.58 | $-0.21 | +64.4% | ✓ BEAT |
Q1 2020 | Mar 27, 2020 | $-0.31 | $-0.35 | -11.4% | ✗ MISS |
Q4 2019 | Nov 19, 2019 | — | $0.03 | — | — |
Q1 2019 | Mar 28, 2019 | — | $-0.22 | — | — |
Q3 2018 | Sep 6, 2018 | — | $0.57 | — | — |
Q1 2018 | Mar 29, 2018 | — | $-0.29 | — | — |
Q3 2017 | Sep 7, 2017 | — | $-0.44 | — | — |
Q1 2017 | Mar 28, 2017 | — | $-0.27 | — | — |
Q3 2016 | Sep 9, 2016 | — | $2.10 | — | — |
Latest News
Frequently Asked Questions about OSE.PA
What is OSE.PA's current stock price?
What is the analyst price target for OSE.PA?
What sector is OSE Immunotherapeutics S.A. in?
What is OSE.PA's market cap?
Does OSE.PA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OSE.PA for comparison